Atezolizumab plus bevacizumab in advanced malignant peritoneal mesothelioma
In a small trial combining PD-L1 and VEGF blockade, four in ten patients with previously treated peritoneal mesothelioma responded, with responses lasting well over a year, the first dedicated prospective evidence for immunotherapy in this rare disease.
Overview
Single-centre phase 2 study of 20 patients with advanced unresectable peritoneal mesothelioma progressing after platinum-pemetrexed, treated with atezolizumab and bevacizumab.
Objective response was 40 percent with a median duration of response of 12.8 months, one-year progression-free survival 61 percent and one-year overall survival 85 percent; biomarker analyses linked response to epithelial-mesenchymal transition and immune features.
- Objective response 40 percent; median duration of response 12.8 months.
- One-year overall survival 85 percent.
Immunotherapy combinations, largely extrapolated from pleural trials, now have direct supporting data in peritoneal mesothelioma and are used after or instead of chemotherapy in unresectable disease.
- Twenty patients at a single centre; no comparator.
Similar pages
not linked directly; found by shared links- TrialA Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma
Shares Atezolizumab, Bevacizumab.
- TrialA Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)
Shares Atezolizumab, Bevacizumab.
- TrialA Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
Shares Atezolizumab, Bevacizumab.
- TrialA Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirr
Shares Atezolizumab, Bevacizumab.
- TrialAn Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)
Shares Atezolizumab, Bevacizumab.
- TrialA Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocell
Shares Atezolizumab, Bevacizumab.
- TrialStudy of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
Shares Atezolizumab, Bevacizumab.
- Key paperIMbrave050: adjuvant atezolizumab plus bevacizumab versus active surveillance after resection or ablation of high-risk hepatocellular carcinoma
Shares Atezolizumab, Bevacizumab.